Laurent Chardonnet - 23 May 2023 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)

Role
Chief Financial Officer
Signature
/s/ Bryant D. Lim, as Attorney-in-Fact
Issuer symbol
PRLD
Transactions as of
23 May 2023
Net transactions value
+$27,500
Form type
4
Filing time
25 May 2023, 16:05:57 UTC
Previous filing
09 Feb 2023
Next filing
04 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PRLD Common Stock Purchase $27,500 +5,000 +13% $5.50 42,165 23 May 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported total includes 1,292 shares of common stock the reporting person has acquired since the date of his last ownership report through the issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c).